DOCSLIB.ORG

Original Article the Role of TNF-Α and IFN-Γ in the Formation of Osteoclasts and Bone Absorption in Bone Tuberculosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Original Article the Role of TNF-Α and IFN-Γ in the Formation of Osteoclasts and Bone Absorption in Bone Tuberculosis Int J Clin Exp Pathol 2016;9(8):8406-8414 www.ijcep.com /ISSN:1936-2625/IJCEP0025163 Original Article The role of TNF-α and IFN-γ in the formation of osteoclasts and bone absorption in bone tuberculosis Zhong Li1, Housen Jiang1, Xuedong Yang1, Lin Shi1, Junhua Liu2, Xiaoqi Zhang3 1Hand and Foot Bone Surgery of Weifang City People’s Hospital, Weifang 261041, Shandong, China; 2Medicine of Shou Guang City People’s Hospital, Weifang 262700, Shandong, China; 3The Second People’s Hospital Tuberculo- sis of Weifang City, Weifang 261041, Shandong, China Received January 28, 2016; Accepted May 20, 2016; Epub August 1, 2016; Published August 15, 2016 Abstract: Bone-joint tuberculosis is one lytic bone lesion caused by Tubercle bacilli. Tumor necrosis factor (TNF)-α interferon (IFN)-γ can mediate bone formation and osteoclasts. This study aimed to investigate the effect of these factors in the effect of Tubercle bacilli on osteoclast formation and bone absorption. Bone marrow mononuclear cells were separated and generated for osteoblast-osteoclast co-culture system. The effect of Mt sonicate on os- teoclast formation and bone absorption was observed, with the correlation analysis between TNF-α and IFN-γ con- centration. Real-time PCR was employed to detect mRNA expression of receptor activator NF-κB ligand (RANKL) and osteoprotegerin (OPG) in osteoblasts. Immunofluorescence was used to quantify NFATc1 protein level. Antibody against TNF-α and IFN-γ was applied for observing bone absorption. Mt sonicate significantly enhance osteoclast formation and bone absorption and facilitate secretion of TNF-α and IFN-γ. It can also elevate mRNA expression of RANKL and OPG in osteoblast and decrease NFATc1 in osteoclast. The block of TNF-α or IFN-γ significantly weaken Mt sonicate-induced osteoclast formation and bone absorption, facilitate OPG expression, and decrease RNAKL and NFATc1 expression. Tubercle bacilli induced release of TNF-α and IFN-γ is important for bone absorption. TNF-α and IFN-γ interfere the interaction between osteoclast and osteoblast, causing bone destruction, via the modulation on the expression of OPG and RANKL in osteoblast. Keywords: Tuberculosis, bone-joint, inflammatory cytokine, TNF-α, IFN-γ Introduction Host immune function plays important roles on TB growth. Once infected with TB, body will initi- Tuberculosis is one severe infectious disease ate related immune reaction involving multiple caused by Tubercle bacilli (TB) [1]. Osteoarticular immune cells and inflammatory factors to man- tuberculosis (OAT) can be spread to bone and age infection [3, 4]. With the invasion of TB, joint tissues by TB, causing bone destruction innate immune cells including macrophage, NK and absorption featured with inflammatory infil- cells and dendritic cells are rapidly activated to tration. OAT has atypical asymptotic and inva- release multiple inflammatory factors such as sive manifestation, as lesion is featured with bone destruction and lysis, which has persis- interferon (IFN)-γ, tumor necrosis factor (TNF)-α, tence and slow inhalation [2]. The healthy mor- and interleukin (IL)-1, inducing protective infla- phology and normal bone volume depend on mmatory response for exerting immune clear- the dynamic balance between osteoblast and ance [5]. The over-production of protective anti- osteoclast. When certain pathological factor inflammatory factors, however, can interfere makes the enhancement of osteoclast function with the immune clearance against TB. In OAT beyond the compensatory mechanism of osteo- lesion featured with tuberculous granuloma, blast, bone absorption and destruction will both protective and pathological abnormality occur. There are multiple studies regarding the immune response co-exists, but having large mechanism of destruction by pulmonary tuber- difference regarding induced immune cells and culosis. However, the detailed mechanism of inflammatory factors [6]. Generally speaking, bone destruction during OAT is still unclear. protective immunity is mainly achieved via mac- Bone tuberculosis and cytokines rophage activation by CD4 Th cells via IFN-γ, with 10 mL α-MEM basic medium. After cen- while pathological abnormality reaction is trifugation at 1 200 rpm for 5 min, the superna- induced by delayed hypersensitive T cells via tant was discarded. α-MEM medium containing TNF-α and IL-1 [6]. Various inflammatory factors 10% FBS and 1% streptomycin/penicillin was involving in anti-TB immunity, also play impor- added to re-suspend cell spheres, which were tant roles in mediating osteoblast and osteo- then incubated at 37°C chamber with 5% CO2 clast functions. Multiple studies revealed that perfusion. With changing medium every three both TNF-α and IFN-γ could regulate differentia- days, few fibroblast-like attachment cells can tion and biological functions of osteoblast and be observed. Cells were further incubated until osteoclast via multiple pathways [7]. Whether reaching complete fusion (P0), 0.05% trypsin TNF-α and IFN-γ plays a role in OAT caused by was used to digest cells for passage. When P1 TB, is still unclear. generation cell reaches confluence of 60%~80%, osteoblast induction differentiation Materials and methods medium was used for changing every three days in 14-day induction differentiation incuba- Reagent and materials tion. The basic formation of osteoblast can be Low-glucose DMEM, α-MEM, FBS and osteo- observed by Alizarin red S staining. Osteoblasts blast induction differentiation medium (Gibco, were further passed until P2 generation for fur- US); Anti-tartaric acid phosphatase (TRAP) ther experiments. staining kit (Beyotime, China); ELISA kits for human TNF-α and IFN-γ (eBioscience, US); Osteoclast induction and Mt sonicate process- Human recombinant M-CSF (Peprotech, US); ing TB strain H37rv (Pharmaceutical Biological Double volumes of α-MEM medium were used Products Analysis Institute, China); PCR primer to dilute bone marrow, and were centrifuged at (Sangon, China); Fluorescent quantitative PCR 1 200 rpm for 5 min. Supernatant was discard- kit (Toyobo, Japan); Rabbit anti-human NFATc1 ed, with the addition of α-MEM medium con- monoclonal antibody (Abcam, US); Rabbit anti- taining 10% FBS, 20 ng/mL M-CSF and 1% TNF-α and mouse anti-IFN-γ body (R&D, US). streptomycin/penicillin to re-suspend cells. Processing of TB After adjusting 1 × 107/mL concentration, cells were seeded into 24-well plate with or without Mycobacterium tuberculosis H37rv suspen- cortical bone (0.5 mL each). Mt sonicate treat- sions were lysed under intermittent ultrasound ment groups at different concentrations (0 μg/ at 4°C for 60 min. Bacterial mixture was then mL, 0.1 μg/mL, 1 μg/mL, 10 μg/mL and 100 centrifuged at 2 500 rpm for 60 min, followed μg/mL) were prepared for changing medium by filtration through 0.22 μm filter, aliquoted, every 72 h in 8 consecutive days. In addition, to and frozen to prepare lyophilized powder, which better observe the effect of TNF-α and IFN-γ on were kept at 4°C for further use. osteoblast and osteoclast functions under Mt sonicate treatment, we further replenished Preparing calf cortical bone blocker groups including anti-TNF-α (50 ng/mL) Fresh cortical bones from calf limbs were cut and/or anti-IFN-γ (100 ng/mL), in parallel to into bone fraction (50 mm × 50 mm) and were control group using 100 μg/mL Mt sonicate, to smoothing. After fixation in 5% glutaraldehyde test related indexes. for 2 h, bone fraction was cut into sclerite, Establishment of co-culture system which was dehydrated in gradient ethanol. 0.25 mol/L ammonia was used to wash sclerite for Low-glucose DMEM medium containing 10% three times. After γ-irradiation for sterilization, FBS was added into the upper chamber of sclerite was immersed in 1000 U/mL strepto- Transwell for inoculation of induced P2 osteo- mycin/penicillin (in PBS) and was kept at 4°C blast. Transwell chambers were then placed for storage. into 24-well chamber containing osteoclasts Induction of osteoblast after treating using different concentrations of Mt sonicate. After 72 h incubation, culture 5 mL bone marrow samples were drawn from medium in the lower chamber was collected to ilium bone grafting patients, and were mixed quantify TNF-α and IFN-γ using ELISA approach. 8407 Int J Clin Exp Pathol 2016;9(8):8406-8414 Bone tuberculosis and cytokines Table 1. TNF-α, IFN-γ, osteoclast counting and bone absorption under Mt sonicate (N = 10) Bone absorption Bone absorption area Group Osteoclast TNF-α (pg/mL) IFN-γ (pg/mL) lacunae (μm2) 0 μg/mL 2.61±0.91 2.45±0.87 92.13±8.62 97.56±10.46 84.31±12.45 0.1 μg/mL 4.23±1.02 4.04±1.11 98.72±10.17 104.31±11.34 88.43±11.87 1 μg/mL 9.56±2.67a 7.67±2.33a 325.67±36.95a 228.78±21.66a 138.56±15.75a 10 μg/mL 21.54±4.53a 19.45±3.88a 3617.56±77.59a 356.73±31.82a 257.55±30.64a 100 μg/mL 65.25±9.21a 62.64±10.43a 15293.73±291.48a 768.26±41.45a 448.24±39.61a Note: a, P < 0.05 compared to 0 μg/mL group. Observation of bone absorptive lacunae and ddH2O were added. Reaction conditions were: osteoclast 95°C denature for 5 min, followed by 40 cycles each containing 95°C for 15 sec, and 60°C for Cells in 24-well plate without cortical bone were 1 min. Data were collected from ABI ViiA7 fluo- incubated for 8 days. Culture medium was dis- rescent quantitative PCR cycler, and were ana- carded, followed by the staining by TRAP kit. lyzed by 2ΔΔCt method. Under inverted microscope, those large cells with more than three nuclear with TRAP-positive Western blotting staining were identified as osteoclasts. Five fields were randomly selected under 10X objec- Nuclear proteins were extracted, separated in tive to count the number of osteoclasts.
Load more

Recommended publications
  • Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection Against Classical Swine Fever Virus
    Article Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus Yusmel Sordo-Puga 1, Marisela Suárez-Pedroso 1 , Paula Naranjo-Valdéz 2, Danny Pérez-Pérez 1, Elaine Santana-Rodríguez 1, Talia Sardinas-Gonzalez 1, Mary Karla Mendez-Orta 1, Carlos A. Duarte-Cano 1, Mario Pablo Estrada-Garcia 1 and María Pilar Rodríguez-Moltó 1,* 1 Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba; [email protected] (Y.S.-P.); [email protected] (M.S.-P.); [email protected] (D.P.-P.); [email protected] (E.S.-R.); [email protected] (T.S.-G.); [email protected] (M.K.M.O.); [email protected] (C.A.D.); [email protected] (M.P.E.) 2 Central Laboratory Unit for Animal Health (ULCSA), Havana 11400, Cuba; [email protected] * Correspondence: [email protected]; Tel.: +53-7-2504419 Abstract: Live attenuated C-strain classical swine fever vaccines provide early onset protection. These vaccines confer effective protection against the disease at 5–7 days post-vaccination. It was previously reported that intramuscular administration of the Porvac® vaccine protects against highly virulent Citation: Sordo-Puga, Y.; classical swine fever virus (CSFV) “Margarita” strain as early as seven days post-vaccination. In Suárez-Pedroso, M.; Naranjo-Valdéz, order to identify how rapidly protection against CSFV is conferred after a single dose of the Porvac® P.; Pérez-Pérez, D.; subunit vaccine E2-CD154, 15 swine, vaccinated with a single dose of Porvac®, were challenged Santana-Rodríguez, E.; 3 intranasally at five, three, and one day post-vaccination with 2 × 10 LD50 of the highly pathogenic Sardinas-Gonzalez, T.; Mendez-Orta, Cuban “Margarita” strain of the classical swine fever virus.
    [Show full text]
  • Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future
    veterinary sciences Review Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future Sara Frazzini 1 , Federica Riva 2,* and Massimo Amadori 3 1 Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] 2 Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, 26900 Lodi, Italy 3 Rete Nazionale di Immunologia Veterinaria, 25125 Brescia, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0250334519 Abstract: Cytokines are important molecules that orchestrate the immune response. Given their role, cytokines have been explored as drugs in immunotherapy in the fight against different pathological conditions such as bacterial and viral infections, autoimmune diseases, transplantation and cancer. One of the problems related to their administration consists in the definition of the correct dose to avoid severe side effects. In the 70s and 80s different studies demonstrated the efficacy of cytokines in veterinary medicine, but soon the investigations were abandoned in favor of more profitable drugs such as antibiotics. Recently, the World Health Organization has deeply discouraged the use of antibiotics in order to reduce the spread of multi-drug resistant microorganisms. In this respect, the use of cytokines to prevent or ameliorate infectious diseases has been highlighted, and several studies show the potential of their use in therapy and prophylaxis also in the veterinary field. In this review we aim to review the principles of cytokine treatments, mainly IFNs, and to update the experiences encountered in animals. Keywords: veterinary immunotherapy; cytokines; IFN; low dose treatment; oral treatment Citation: Frazzini, S.; Riva, F.; Amadori, M.
    [Show full text]
  • Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications
    International Journal of Molecular Sciences Review Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications Sandra Maria Barbalho 1,2,3,* , Uri Adrian Prync Flato 1,2 , Ricardo José Tofano 1,2, Ricardo de Alvares Goulart 1, Elen Landgraf Guiguer 1,2,3 , Cláudia Rucco P. Detregiachi 1 , Daniela Vieira Buchaim 1,4, Adriano Cressoni Araújo 1,2 , Rogério Leone Buchaim 1,5, Fábio Tadeu Rodrigues Reina 1, Piero Biteli 1, Daniela O. B. Rodrigues Reina 1 and Marcelo Dib Bechara 2 1 Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marilia (UNIMAR), Avenue Hygino Muzzy Filho, 1001, Marília 17525-902, São Paulo, Brazil; urifl[email protected] (U.A.P.F.); [email protected] (R.J.T.); [email protected] (R.d.A.G.); [email protected] (E.L.G.); [email protected] (C.R.P.D.); [email protected] (D.V.B.); [email protected] (A.C.A.); [email protected] (R.L.B.); [email protected] (F.T.R.R.); [email protected] (P.B.); [email protected] (D.O.B.R.R.) 2 School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17506-000, São Paulo, Brazil; [email protected] 3 Department of Biochemistry and Nutrition, Food Technology School, Marília 17525-902, São Paulo, Brazil 4 Medical School, University Center of Adamantina (UniFAI), Adamantina 17800-000, São Paulo, Brazil 5 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo (FOB–USP), Alameda Doutor Octávio Pinheiro Brisolla, 9-75, Bauru 17012901, São Paulo, Brazil * Correspondence: [email protected]; Tel.: +55-14-99655-3190 Received: 6 May 2020; Accepted: 19 May 2020; Published: 20 May 2020 Abstract: Skeletal muscle is capable of secreting different factors in order to communicate with other tissues.
    [Show full text]
  • Increased Peripheral Blood Inflammatory Cytokine Levels In
    www.nature.com/scientificreports OPEN Increased peripheral blood infammatory cytokine levels in amyotrophic lateral sclerosis: a Received: 3 May 2017 Accepted: 20 July 2017 meta-analysis study Published: xx xx xxxx Yang Hu, Chang Cao, Xiao-Yan Qin, Yun Yu, Jing Yuan, Yu Zhao & Yong Cheng Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with poorly understood etiology. Increasing evidence suggest that infammation may play a critical role in the pathogenesis of ALS. Several studies have demonstrated altered levels of blood cytokines in ALS, but results were inconsistent. Therefore, we did a systematic review of studies comparing blood infammatory cytokines between ALS patients and control subjects, and quantitatively combined the clinical data with a meta- analysis. The systematic review of Pubmed and Web of Science identifed 25 studies encompassing 812 ALS patients and 639 control subjects. Random-efects meta-analysis demonstrated that blood tumor necrosis factor-α (TNF; Hedges’ g = 0.655; p = 0.001), TNF receptor 1 (Hedges’ g = 0.741; p < 0.001), interleukin 6 (IL-6; Hedges’ g = 0.25; p = 0.005), IL-1β (Hedges’ g = 0.296; p = 0.038), IL-8 (Hedges’ g = 0.449; p < 0.001) and vascular endothelial growth factor (Hedges’ g = 0.891; p = 0.003) levels were signifcantly elevated in patients with ALS compared with control subjects. These results substantially enhance our knowledge of the infammatory response in ALS, and peripheral blood infammatory cytokines may be used as diagnostic biomarkers for ALS in the future. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal neurodegenerative disease characterized by the degeneration of motor neurons in brain and spinal cord1.
    [Show full text]
  • Expression of Osteopontin, Interleukin 17 and Interleukin 10 Among Rheumatoid Arthritis Sudanese Patients
    Arch Microbiol Immunology 2020; 4 (4): 131-138 10.26502/ami.93650052 Original Article Expression of Osteopontin, Interleukin 17 and Interleukin 10 among Rheumatoid Arthritis Sudanese Patients Mohamed A Eltahir1, Amar M Ismail2, Elhaj NM Babiker1, Mohammed KA Karrar1, Kawthar A Mohammed S Alih3* 1Department of Clinical Chemistry, Faculty of Medical Laboratory Science, Sudan University of Science and Technology, Khartoum, Sudan 2Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, Al-Neelain University, Khartoum, Sudan 3General Department, Faculty of Medical Laboratory Science, Sudan University of Science and Technology, Khartoum, Sudan *Corresponding Author: Kawthar A Mohammed S Alih, General Department, Faculty of Medical Laboratory Science, Sudan University of Science and Technology, Khartoum, Sudan; E-mail: [email protected] Received: 22 October 2020; Accepted: 03 November 2020; Published: 18 November 2020 Citation: Mohamed A Eltahir, Amar M Ismail, Elhaj NM Babiker, Mohammed KA Karrar, Kawthar A Mohammed S Alih. Expression of Osteopontin, Interleukin 17 and Interleukin 10 among Rheumatoid Arthritis Sudanese Patients. Archives of Microbiology & Immunology 4 (2020): 131-138. Abstract Materials and Methods: A case control hospital Background: Rheumatoid arthritis (RA) is the based study for groups of 88 rheumatoid arthritis most common inflammatory arthritis in the world. patients was included from Outpatient Clinic. The Its exact cause is unknown; proinflammatory and control groups matched in numbers, age and sex anti inflammatory cytokines play key roles in the with case. After inform consent, Serum from Both pathophysiology of disease. patients and controls were examined for OPN, IL- 17 and IL-10. Objectives: This study aimed to measure the level of pro inflammatory cytokines Osteopontin (OPN) Results: The mean age of RA patients was 41.0 and interleukin (IL-17) and anti-inflammatory ±11.7 years.
    [Show full text]
  • Antigen-Specific Induced Foxp3 Regulatory T Cells Are Generated
    Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade Ivana R. Ferrer, Maylene E. Wagener, Minqing Song, Allan D. Kirk, Christian P. Larsen, and Mandy L. Ford1 Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA 30322 Edited by James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved November 4, 2011 (received for review April 7, 2011) Blockade of the CD40/CD154 pathway potently attenuates T-cell in vivo accumulation of Treg and deletion of graft-specific ef- responses in models of autoimmunity, inflammation, and trans- fectors after CD40/CD154 blockade has not been investigated. plantation. Indeed, CD40 pathway blockade remains one of the To address these questions, we used an ovalbumin (OVA)- most powerful methods of prolonging graft survival in models of expressing transgenic mouse model (20), which allowed us to di- + + transplantation. But despite this effectiveness, the cellular and rectly track both donor-reactive CD4 and CD8 T-cell responses molecular mechanisms underlying the protective effects of CD40 simultaneously over time. Although previous studies have used pathway blockade are incompletely understood. Furthermore, the transgenic models to assess the degree of T-cell deletion after CD154/CD40 blockade (16, 21), none has systematically inter- relative contributions of deletion, anergy, and regulation have not + been measured in a model in which donor-reactive CD4+ and CD8+ rogated the impact of anti-CD154 on the kinetics of both CD4 and CD8+ T-cell deletion and acquisition of effector function. T-cell responses can be assessed simultaneously. To investigate the fi Our results indicated that although CD40/CD154 blockade alone impact of CD40/CD154 pathway blockade on graft-speci c T-cell delayed donor-reactive CD4+ and CD8+ T-cell expansion and responses, a transgenic mouse model was used in which recipients differentiation, the addition of DST was required for antigen- fi + + containing ovalbumin-speci cCD4 and CD8 TCR transgenic T specific T-cell deletion.
    [Show full text]
  • Interferon Gamma Release Assay (IGRA) Interferon Gamma Release Assay (IGRA) Is a Blood Test That Has Recently Been Introduced As Another Method to Diagnose LTBI
    Section 4: TB Screening These cases also included patients that did not have previous exposure to tuberculin. It is imperative that health care providers should have Epinephrine Hypochloride solution (1:1000) and other appropriate agents available for immediate use in the case of a hypersensitivity reaction. As per NACI, recommendations all patients must be monitored for 15 minutes after inoculation. Interferon Gamma Release Assay (IGRA) Interferon gamma release assay (IGRA) is a blood test that has recently been introduced as another method to diagnose LTBI. Therefore, it can complement the TST in certain situations. In general, IGRAs are more specific than the TST in populations vaccinated with BCG, especially if BCG is given after infancy or multiple times. When a person is exposed to MTB it produces many immune cells, which produce various proteins. Among these proteins are interferon gamma or IFN-y. The interferon gamma release assay (IGRA) is a blood test that measures IFN-y. Therefore, if a person has been exposed and infected with TB, IFN-y can be detected with this test. There are two IGRA tests used in Canada, the T-SPOT.TB test and the QuantiFERON®-TB Gold test. Provincial Laboratory (ProvLab) Alberta uses QuantiFERON®-TB Gold (QFT) test in the NWT. Specimens must be received by the regional laboratory and incubated for 16–24 hours. This limits availability of this test in the NWT. IGRA can only be ordered through the Office of the Chief Public Health Officer and Stanton Regional Hospital Specialists who are involved in TB management and treatment. IGRAs require laboratories with adequate equipment and trained personnel to perform the assays.
    [Show full text]
  • Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
    Review Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation Leonor S. Castro 1,†, Guilherme S. Lobo 1,†, Patrícia Pereira 2 , Mara G. Freire 1 ,Márcia C. Neves 1,* and Augusto Q. Pedro 1,* 1 CICECO–Aveiro Institute of Materials, Chemistry Department, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; [email protected] (L.S.C.); [email protected] (G.S.L.); [email protected] (M.G.F.) 2 Centre for Mechanical Engineering, Materials and Processes, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Polo II, 3030-790 Coimbra, Portugal; [email protected] * Correspondence: [email protected] (M.C.N.); [email protected] (A.Q.P.) † These authors contributed equally to this work. Abstract: The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and their derivatives accounting for most of the generated revenues. The success of pharmaceutical biotechnology is closely linked with remarkable developments in DNA recombinant technology, which has enabled the production of proteins with high specificity. Among promising biopharmaceuticals are interferons, first described by Isaacs and Lindenmann in 1957 and approved for clinical use in humans nearly thirty years later. Interferons are secreted autocrine and paracrine proteins, which by regulating several biochemical Citation: Castro, L.S.; Lobo, G.S.; pathways have a spectrum of clinical effectiveness against viral infections, malignant diseases, Pereira, P.; Freire, M.G.; Neves, M.C.; and multiple sclerosis.
    [Show full text]
  • 2010 Hepatitis C Treatment Updates
    2010 Hepatitis C Treatment Updates Summer 2010 Treatment Options Conventional Interferon Alone (Monotherapy) Studies in adults have demonstrated that monotherapy with conventional interferon is effective for adults 10-15% of the time. Although children typically respond better than adults to this treatment (27% for genotype 1 and 71% for genotype 2 and 3), subsequent study has confirmed that using conventional interferon in combination with ribavirin produces better treatment outcomes for both adults and children. Thus, conventional interferon alone is no longer recommended for the majority of children requiring HCV therapy. Conventional Interferon Alpha-2b in Combination with Ribavirin (Rebetron for Children) Rebetron was the first drug to be FDA-approved to treat children with hepatitis C. It’s approved for use in children between the ages of 5 and 16 years. Rebetron is a combination drug that contains both Intron A (an interferon alfa-2b) and Rebetol (which is ribavirin). Rebetron is administered as a weight-based dose of oral Rebetol that is taken twice a day. (Rebetol should never be used alone to treat hepatitis C.) The Intron A portion of the treatment is a subcutaneous injection that is given three times weekly for 24 to 48 weeks. Sometimes, problems with anemia or depression can develop with this treatment. When this occurs, doses should be reduced temporarily or permanently until the problem is reversed. Additionally, if uncontrollable thyroid abnormalities (such has hypothyroidism) occur, treatment should be discontinued. Use of conventional interferon alpha-2b in combination with ribavirin has been shown to improve treatment outcomes in adults when compared to using conventional interferon alone.
    [Show full text]
  • High Sensitivity Immunoassays for Detecting Ifn-Gamma in Cytokine Release Syndrome
    APPLICATION NOTE HIGH SENSITIVITY IMMUNOASSAYS FOR DETECTING IFN-GAMMA IN CYTOKINE RELEASE SYNDROME INTRODUCTION T cell expansion with increased Interferon Gamma (IFN-γ) release. Note that increased IFN-γ is also an early and prominent element of CRS. IFN , along with IL-6, IL-10 and TNF-alpha are the Cytokine Release Syndrome (CRS), also known as the “Cytokine -γ core cytokines involved in CRS (2). IFN activates macrophages Storm”, is a systemic inflammatory response characterized at the -γ which secrete excessive amounts of other cytokines such as cellular level by the rapid release of excessive concentrations IL-6, TNF and IL-10. Lastly, it is important to keep in mind that of cytokines (1,2). Patient symptoms range from mild fever to α IFN is pleiotropic and has both harmful and beneficial effects. hypotension, multiorgan system failure, neurotoxicity and death. -γ Although IFN has a harmful role in CRS, it also been correlated CRS is caused by a variety of events, including viral infection, -γ with antiproliferative, proapoptotic and antitumor activities in the antibody-based immunotherapy and cellular immunotherapy. context of cancer (4). In antibody-based immunotherapies, the incidence of CRS is relatively low, however, onset can occur within days and up to We previously described the new 3rd generation R&D Systems® weeks of infusion in cellular immunotherapy. Evidence suggests IFN-γ Quantikine® ELISA kit. Learn more about that assay here. that the risk and severity of CRS is influenced by the type of Here, we describe the R&D Systems® Human IFN-γ Quantikine® therapy, disease burden and patient characteristics, such as age.
    [Show full text]
  • Role of Mitogen-Activated Kinases in Cd40-Mediated T Cell Activation of Monocyte/ Macrophage and Vascular Smooth Muscle Cell Cytokine/Chemokine Production Denise M
    East Tennessee State University Digital Commons @ East Tennessee State University Electronic Theses and Dissertations Student Works August 1999 Role of Mitogen-activated Kinases in Cd40-mediated T Cell Activation of Monocyte/ macrophage and Vascular Smooth Muscle Cell Cytokine/chemokine Production Denise M. Milhorn East Tennessee State University Follow this and additional works at: https://dc.etsu.edu/etd Part of the Immunology and Infectious Disease Commons Recommended Citation Milhorn, Denise M., "Role of Mitogen-activated Kinases in Cd40-mediated T Cell Activation of Monocyte/macrophage and Vascular Smooth Muscle Cell Cytokine/chemokine Production" (1999). Electronic Theses and Dissertations. Paper 2950. https://dc.etsu.edu/ etd/2950 This Dissertation - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quaiity of the copy subm itted. Broken or indistinct print, colored or poor quality illustrations arxf photographs, print bleedthrough. sutwtandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete m anuscrit and there are missing pages, these wiH be noted.
    [Show full text]
  • Betaferon Data Sheet
    NEW ZEALAND DATA SHEET 1 PRODUCT NAME BETAFERON® Interferon beta-1b 8 MIU Injection with diluent 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Lyophilisate and solvent for solution for injection. BETAFERON® Recombinant Interferon beta-1b 0.25 mg (8.0 million IU) per mL when reconstituted. 1 mL of the reconstituted solution for injection contains 8 million IU (0.25 mg) of interferon beta-1b. 1 mL solution for injection contains 5.4 mg sodium chloride. Interferon beta-1b is produced in Escherichia coli cells by recombinant DNA technology from a strain of Escherichia coli that bears a genetically engineered plasmid containing a modified human interferon beta gene. BETAFERON contains mannitol. For the full list of Excipients, see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM BETAFERON is presented as a sterile lyophilised white to off-white cake or powder and solvent for solution for injection. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications BETAFERON is indicated for: • the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (MRI) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded, • the treatment of ambulatory patients, with relapsing-remitting multiple sclerosis (MS) characterised by at least two attacks of neurological dysfunction over a two year period followed by complete or incomplete recovery. • the reduction of frequency and severity of clinical relapses and for slowing the progression of disease in patients with secondary progressive multiple sclerosis 4.2 Dose and method of administration General Treatment with BETAFERON should be initiated under the supervision of a physician experienced in the treatment of multiple sclerosis.
    [Show full text]